New Pharmaceuticals market report from Global Markets Direct: "Type 2 Diabetes - Pipeline Review, H1 2014"
Boston, MA -- (SBWIRE) -- 04/10/2014 -- Global Markets Direct's, 'Type 2 Diabetes - Pipeline Review, H1 2014', provides an overview of the Type 2 Diabetes's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.
View Full Report Details and Table of Contents
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Type 2 Diabetes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Type 2 Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Type 2 Diabetes pipeline on the basis of target, MoA, route of administration and molecule type
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Shionogi & Co., Ltd., Amgen Inc., Sanofi, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, MedImmune, LLC, Isis Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo Company, Limited, Merck & Co., Inc., Dainippon Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Euroscreen S.A., Novo Nordisk A/S, Generex Biotechnology Corporation, Takeda Pharmaceutical Company Limited, FibroGen, Inc., Ipsen S.A., Piramal Enterprises Limited, Neurocrine Biosciences, Inc., Teijin Pharma Limited, Novartis AG, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Forest Laboratories, Inc., Glenmark Pharmaceuticals Ltd., Japan Tobacco Inc., Kissei Pharmaceutical Co., Ltd., Les Laboratoires Servier SAS, Mitsubishi Tanabe Pharma Corporation, Pfizer Inc., Ranbaxy Laboratories Limited, Zydus Cadila Healthcare Limited, Hadasit Medical Research Services & Development Ltd, Biodel Inc., Bayer AG, OPKO Health, Inc., MannKind Corporation, Halozyme Therapeutics, Inc., Toray Industries, Inc., Merck KGaA, Alchemia Limited, Addex Therapeutics, Evotec AG, AlbireoPharma, GW Pharmaceuticals plc, Harbor Therapeutics, Inc., Enzo Biochem, Inc., Genfit SA, Ligand Pharmaceuticals, Inc., Mesoblast Limited, Oramed Pharmaceuticals, Inc., Orchid Chemicals & Pharmaceuticals Ltd, ConjuChem Biotechnologies Inc., Lexicon Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., Flamel Technologies S.A., CSL Limited, ProteoTech, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Yuhan Corporation, XOMA Corporation, Immuron Limited, IPCA Laboratories Limited, Xenetic Biosciences plc, Handok Inc., Hyundai Pharmaceutical Co., Ltd., LG Life Sciences, Ltd., Transition Therapeutics Inc., Jiangsu Hengrui Medicine Co., Ltd., Uni-Bio Science Group Ltd., Panacea Biotec Limited, Summit Corporation plc, Phynova Group Ltd, Genovate Biotechnology Co., LTD., DiaMedica Inc., NeuroVive Pharmaceutical AB, Angelini Group, Debiopharm International S.A., Advinus Therapeutics Ltd., CJ CheilJedang Corp., Chipscreen Biosciences Ltd, Aurigene Discovery Technologies Limited, ActogeniX NV, Camurus AB, Jenrin Discovery, Inc., reMYND, Wellstat Therapeutics Corporation, Celon Pharma Sp. z o.o., Cortendo Invest AB, Anchor Therapeutics, Inc., Arisaph Pharmaceuticals, Inc., Protemix Corporation Limited, Allozyne, Inc., Metabolic Solutions Development Co., Zafgen Inc., Catabasis Pharmaceuticals, Inc., PhaseBio Pharmaceuticals, Inc., Melior Discovery, Inc., Diabetology Limited, Braasch Biotech LLC, Zealand Pharma A/S, Intarcia Therapeutics, Inc., Theracos, Inc., Versartis, Inc., Kainos Medicine, Inc., Nordic Bioscience a/s, InteKrin Therapeutics, Inc., Virobay Inc., Noxxon Pharma AG, Avaxia Biologics, Inc., Intercept Pharmaceuticals, Inc., Omeros Corporation, TransTech Pharma, Inc., Bridge Bioresearch Plc, Synthetic Biologics, Inc., Targacept, Inc., N-Gene Research Laboratories, Inc., Obio Pharmaceutical Holdings Limited, ChemoCentryx, Inc., USV Limited, Vitae Pharmaceuticals, Inc., CureDM, Inc., Verva Pharmaceuticals Limited, Exsulin Corporation, Medestea Research & Production S.p.A., NasVax Ltd., Stelic Institute & Co., Vybion, Inc., Regulus Therapeutics Inc., Esperion Therapeutics, Inc., Sihuan Pharmaceutical Holdings Group Ltd., NGM Biopharmaceuticals, Inc., Alize Pharma SAS, Ardelyx, Inc., Heptares Therapeutics Ltd., Mitsubishi Pharmaceutical Corporation, Receptos, Inc., MicroDose Therapeutx, Inc., Sirona Biochem Corp, XBiotech USA, Inc., Carmot Therapeutics, Inc., Connexios Life Sciences Pvt. Ltd., Serometrix, LLC, PharmaIN Corporation, Stempeutics Research Private Limited, Serodus ASA, SignPath Pharma Inc, Elcelyx Therapeutics, Inc., Thermalin Diabetes Inc., Selvita S.A, Poxel SA, Medesis Pharma S.A., Kadmon Pharmaceuticals, LLC, Neopharm Co., Ltd., Shanghai Pharmaceuticals Holding Co Ltd, Hanmi Pharmaceuticals, Co. Ltd., Metabolys S.A.S., Boston Therapeutics, Inc., Cardiolynx AG, TWi Pharmaceuticals, Inc., Allinky Biopharma, Rhizen Pharmaceuticals SA, Hua Medicine Ltd., Curaxys, S.L., MidaSol Therapeutics LP, Foresee Pharmaceuticals, LLC, Paras Biopharmaceuticals Finland Oy, CymaBay Therapeutics, Inc., Biospherics.net Incorporated, Dong-A Socio Holdings Co Ltd
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Atherosclerosis - Pipeline Review, H1 2014
- Tuberculosis - Pipeline Review, H1 2014
- Atopic Dermatitis - Pipeline Review, H1 2014
- Parkinson's Disease - Pipeline Review, H1 2014
- Stroke - Pipeline Review, H1 2014
- Small-Cell Lung Cancer - Pipeline Review, H1 2014
- Hypertension - Pipeline Review, H1 2014
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014
- Colon Cancer - Pipeline Review, H1 2014
- Myocardial Infarction - Pipeline Review, H1 2014